Timothy Coughlin - 03 Jun 2025 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Reporting relationship: Director
Issuer ticker: ADCT
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 17:13:04 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 04 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa Kallebo, as Attorney-in-fact for Timothy Coughlin

Key filing fact

Timothy Coughlin filed Form 4 for ADC Therapeutics SA (ADCT) on 05 Jun 2025.

Key facts

This page summarizes Timothy Coughlin's Form 4 filing for ADC Therapeutics SA (ADCT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 17:13.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001376043 Primary reporting owner

COUGHLIN TIMOTHY

Relationship: Director
Address: 430 MOUNTAIN AVENUE, SUITE 404, NEW PROVIDENCE
Signature: /s/ Lisa Kallebo, as Attorney-in-fact for Timothy Coughlin
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADCT transaction

Common Shares

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADCT transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 80,000
Exercise price: $3.59
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Represents a one-time initial stock option award made under the Issuer's 2019 Equity Incentive Plan. The options vest over four years from June 3, 2025, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.